Blood Stem Cell Transplantation

Sprache: Englisch

Verlag: Springer US Mrz 1997, 1997

0792342607 / 9780792342601

Serie: Buch 92 von 180 - Cancer Treatment and Research

Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, DeutschlandBuchWeltWeit Ludwig Meier e.K.

Verkäufer/-in mit 5 Sternen

Verkäufer:in bei AbeBooks seit 11. Januar 2012

Hardcover

Zustand: Neu

EUR 481,49

EUR 23,00 Versand 
Versand von Deutschland nach USA

Anzahl: 2 verfügbar

In den Warenkorb
30 Tage kostenlose Rückgabe

Artikelbeschreibung des Verkäufers

This item is printed on demand - it takes 3-4 days longer - Neuware -Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/or expand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiment 436 pp. Englisch.…

Titel
Blood Stem Cell Transplantation
Autor
Jane N. Winter
Verlag
Springer US Mrz 1997
Erscheinungsjahr
1997
Zustand
Neu
Einband
Buch
Sprache
Englisch
ISBN-10
0792342607
ISBN-13
9780792342601
Artikelgewicht
816 Gramm
Abmessungen
241x160x28 mm
Serie
Buch 92 von 180: Cancer Treatment and Research

BuchWeltWeit Ludwig Meier e.K.

Bergisch Gladbach, Deutschland

Verkäufer/-in mit 5 Sternen

Verkäufer:in bei AbeBooks seit 11. Januar 2012

Versandkosten von Deutschland nach USA

Artikel5 bis 15 Werktage5 bis 15 Werktage
Erster ArtikelEUR 23,00EUR 23,00
Die Versandzeiten werden von den Verkäuferinnen und Verkäufern festgelegt. Sie variieren je nach Versanddienstleister und Standort. Sendungen, die den Zoll passieren, können Verzögerungen unterliegen. Eventuell anfallende Abgaben oder Gebühren sind von der Käuferin bzw. dem Käufer zu tragen. Die Verkäuferin bzw. der Verkäufer kann Sie bezüglich zusätzlicher Versandkosten kontaktieren, um einen möglichen Anstieg der Versandkosten für Ihre Artikel auszugleichen.

Zahlungsarten

  • Visa
  • Mastercard
  • American Express
  • Carte Bleue
  • Apple Pay
  • Google Pay
  • Banküberweisung
  • PayPal
  • Vorauskasse

Unternehmensdaten der Verkäuferin bzw. des Verkäufers

BuchWeltWeit Ludwig Meier e.K.

Deutschland

BuchWeltWeit Inh. Ludwig Meier e.K.
Inhaber: Ludwig Meier
De-Gasperi-Str. 8
51469 Bergisch Gladbach
Deutschland

Tel.: +49(0)22028659300
Fax: +49(0)22028659301
E-Mail: info@buchweltweit.de

Registergericht: Amtsgericht Köln
Registernummer: HRA 28253

Umsatzsteuer-Identifikationsnummer: DE815259907

Wir sind zur Teilnahme an einem Streitbeilegungsverfahren vor einer Verbraucherschlichtungsstelle weder verpflichtet noch bereit.